VTAK Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -2828.67% compared to Catheter Precision's net margin of -0.77%. Catheter Precision's return on equity of -137.84% beat InfuSystems Holdings's return on equity of 5.82%.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 365.12%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.00 which suggests that it could grow by 129.51%. Given that Catheter Precision has higher upside potential than InfuSystems Holdings, analysts believe Catheter Precision is more attractive than InfuSystems Holdings.

Catheter Precision has a beta of -0.850, which suggesting that the stock is 184.968% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.809, suggesting its more volatile than the S&P 500 by 80.854%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Catheter Precision quarterly revenues are $143K, which are smaller than InfuSystems Holdings quarterly revenues of $34.7M. Catheter Precision's net income of -$4M is lower than InfuSystems Holdings's net income of -$267K. Notably, Catheter Precision's price-to-earnings ratio is 0.40x while InfuSystems Holdings's PE ratio is 43.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 4.94x versus 0.96x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -2828.67% compared to Catheter Precision's net margin of -126.59%. Catheter Precision's return on equity of -137.84% beat Retractable Technologies's return on equity of -26.39%.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 365.12%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Catheter Precision has higher upside potential than Retractable Technologies, analysts believe Catheter Precision is more attractive than Retractable Technologies.

Catheter Precision has a beta of -0.850, which suggesting that the stock is 184.968% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.386, suggesting its more volatile than the S&P 500 by 38.583%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Catheter Precision quarterly revenues are $143K, which are smaller than Retractable Technologies quarterly revenues of $8.3M. Catheter Precision's net income of -$4M is higher than Retractable Technologies's net income of -$10.5M. Notably, Catheter Precision's price-to-earnings ratio is 0.40x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 4.94x versus 0.61x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -2828.67% compared to Catheter Precision's net margin of -2201.34%. Catheter Precision's return on equity of -137.84% beat VolitionRX's return on equity of --.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 365.12%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 391.28%. Given that VolitionRX has higher upside potential than Catheter Precision, analysts believe VolitionRX is more attractive than Catheter Precision.

Catheter Precision has a beta of -0.850, which suggesting that the stock is 184.968% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.247%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Catheter Precision quarterly revenues are $143K, which are smaller than VolitionRX quarterly revenues of $246.4K. Catheter Precision's net income of -$4M is higher than VolitionRX's net income of -$5.4M. Notably, Catheter Precision's price-to-earnings ratio is 0.40x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 4.94x versus 41.08x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -2828.67% compared to Catheter Precision's net margin of 0.18%. Catheter Precision's return on equity of -137.84% beat Xtant Medical Holdings's return on equity of -26.62%.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 365.12%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 169.23%. Given that Catheter Precision has higher upside potential than Xtant Medical Holdings, analysts believe Catheter Precision is more attractive than Xtant Medical Holdings.

Catheter Precision has a beta of -0.850, which suggesting that the stock is 184.968% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Catheter Precision quarterly revenues are $143K, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Catheter Precision's net income of -$4M is lower than Xtant Medical Holdings's net income of $58K. Notably, Catheter Precision's price-to-earnings ratio is 0.40x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 4.94x versus 0.73x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.